_Market_Cover_Slide-compressed1.jpg)
Market Definition
Non-Hodgkin Lymphoma (NHL) is cancer that usually starts in the body's lymphatic system, wherein lymphocytes grow abnormally & develop tumors throughout the body. Although NHL mainly occurs in adults, children can get it too. The disease can be lethal if not treated effectively and, in turn, result in a shorter life span for patients. However, various clinical trials conducted by the leading biotechnological & pharmaceutical companies worldwide for new drug developments, particularly for the relapsed & refractory cases, have aided in improving the prognosis for people with Non-Hodgkin Lymphoma.
Market Insights
The Global Non-Hodgkin Lymphoma (NHL) Market is expected to grow at around 7.6% CAGR during the forecast period, i.e., 2022-27. The growth of the market would be driven primarily by the rising prevalence of B-cell lymphoma worldwide and mounting side effects of chemotherapy treatment, which, in turn, is leading to substantial R&D investments in procuring novel drugs to cure NHL. Besides, rapid drug approvals for B-cell lymphoma treatment in both developed & emerging countries and the impressive pipeline of targeted therapies, coupled with the label expansion of currently available therapies for treating various subtypes of NHL, are also driving the market.
| Report Coverage | Details |
|---|---|
| Study Period | Historical Data: 2017-20 |
| Base Year: 2021 | |
| Forecast Period: 2022-27 | |
| CAGR (2022-2027) | 7.6% |
| Regions Covered | North America: The US, Canada, Mexico |
| South America: Brazil, Rest of South America | |
| Europe: Germany, The UK, France, Spain, Italy, Rest of Europe | |
| Asia-Pacific: China, Japan, India, Australia, South East Asia, Rest of Asia Pacific | |
| Middle East & Africa: GCC, South Africa, Rest of Middle East and Africa | |
| Key Companies Profiled | AstraZeneca PLC, AbbVie Inc., Baxter International Inc., Bayer AG, Bristol Myers Squibb, Eli Lilly and Company, GlaxoSmithKline PLC, F. Hoffmann-La Roche AG, Merck & Co., Inc., Novartis International AG, Pfizer Inc., Others |
| Unit Denominations | USD Million/Billion |
Non-Hodgkin Lymphoma is usually more observed across countries with high living standards. BCLs (B-cell lymphomas) account for the majority of NHL cases, whereas FL (Follicular lymphoma) & DLBCL (Diffuse Large B-Cell Lymphoma) are the most common indolent & aggressive subtypes of NHL, respectively. Patients with NHL often require aggressive & accurate modes of treatment due to no show of symptoms, which results in the diagnosis of the disease in advanced stages.
There are different treatment options for NHL, which depend entirely on its subtype & stage. They may include chemotherapy, stem cell transplant, immunotherapy (Monoclonal Antibodies, Antibody-drug Conjugates, Immunomodulatory Drugs, & CAR T-cell therapy), targeted therapies, radiation therapy, & surgery. There are high unmet patient needs for the treatment of Non-Hodgkin Lymphoma, i.e., leading to the launch of promising therapeutic drugs, which will further augment the growth of the Global Non-Hodgkin Lymphoma (NHL) Market through 2027.
_Market_-_Segmentation.png)